Alprostadil

• Fibrinolytic Agents
• Platelet Aggregation Inhibitors
• Vasodilator Agents
• ATC:C01EA01
• ATC:G04BE01

• Alprostadil Prostoglandin E1
• Befar
• Caverject
• Edex
• Muse
• PGE1
• Prink
• Prostaglandin E1
• Prostin VR
• Prostin VR Pediatric
• l-Prostaglandin E1

• No information avaliable

C₂₀H₃₄O₅

http://www.rxlist.com/cgi/generic/alprostadil.htm

Alprostadil FDA

Alprostadil MSDS

No information avaliable

354.481 g/mol

115 - 116 ^oC

26.7 mg/L

Solid

2.983

Liquid; Powder for solution; Solution; Suppository

For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops. This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.

The absolute bioavailability of alprostadil has not been determined.

Oral, mouse: LD₅₀ = 186 mg/kg; Oral, rat: LD₅₀ = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.

Humans and other mammals